<mods:mods version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mods:titleInfo><mods:title>YURAK ISHEMIK KASALLIGI MAVJUD BEMORLARDA  INTERLEYKIN-6 AHAMIYATI</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">G`opirjonova D.D</mods:namePart><mods:namePart type="family">G`opirjonova D.D</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Alyavi A.L</mods:namePart><mods:namePart type="family">Alyavi A.L</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Yallig`lanish bu yurak ishemik kasalligida (YuIK) ishtirok etuvchi muhim jarayon hisoblanadi. Metabolik stress, gemodinamik ortiqcha yuk va endoteliy va miyokard hujayralarida neyrogumaral giperaktivatsiyaga javoban interleykin (IL) 1 va 6 kabi yallig`lanishga qarshi sitokinlar chiqariladi. Dastlab, bu jarayon organizimni stresga moslashishini taminlaydi, ammo keyinchlik kasallik davrida ular endothelial va yurak disfunktsiyasi orqali miyokard fibroziga olib keladigan zararli ta`sirlarni keltirib chiqaradi. Tadqiqotlar shuni ko`rsatadiki yurak ishemik kasalligida bemorlarda interleykin(IL)6 yallig`lanish mediatori ko`payib ketadi.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2024-05-15</mods:dateIssued></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>